SERUM INFLAMMATORY BIOMARKERS IN HEPATOBILIARY CANCER PATIENTS

Objective: To determine the serum inflammatory biomarkers in hepatobiliary cancer patients. Patients And Methods: A total of fifty patients fulfilling inclusion criteria were individuals with hepatobiliary cancer classified as stage IV disease were recruited in this two year cross sectional study (2015-17) conducted at tertiary care hospital. Patient demographic and clinicopathological characteristics and biochemical markers were investigated. Biochemical markers, including serum ferritin, Hb, total bilirubin, AST, alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (γ-GT), prothrombin time international normalized ratio (PT INR), albumin, WBC, and C-reactive protein (CRP), were assessed from peripheral blood testing whereas the frequency / percentages (%) and means ±SD computed for study variables. Results: During six month study period total fifty patients having hepatobiliary cancers were explored and study. The mean ± SD for age (yrs) of population was 52.86±7.85. Raised Serum ferritin 32 (64%), low hemoglobin level 28 (56%), raised bilirubin 15 (30%), raised AST 18 (36%), raised ALT 21 (42%), low albumin 12 (24%), raised TLC 30 (60%) and raised CRP 16 (32%). Conclusion: The increased serum ferritin was significantly associated with poor survival outcome, showing positive correlation with CRP as well. Keywords: Ferritin, inflammatory markers and hepatobiliary cancer